---
title: "Angiotensin (1-7) Analog"
canonical_url: https://peptidelibrary.app/library/ang-1-7-analog
description: "Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Angiotensin (1-7) Analog

Angiotensin (1-7) Analog, also called AVE0991 or Mas-receptor agonist, is a mas receptor agonist in the MasR agonist class. Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.

Also known as: AVE0991, Mas-receptor agonist, Angiotensin-(1-7) analog.

Categories: Fat Loss, GLP-1/Metabolic, Experimental.

## Classification

- Type: Mas receptor agonist / research
- Mechanism class: MasR agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

Targets: Mas receptor (MAS1).

Origin: Synthetic Mas-receptor agonist (AVE0991 is non-peptide).

## Properties

- Half-life: Short; orally active analog tested in rodents

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 2
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress. Psychopharmacology (Berl). 2026. 2026. Preclinical: animal or lab study. Population: Male mice. Lower stress hormone and blood glucose, less anxiety- and depression-like behaviour. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/42440117/)
2. AVE0991, a nonpeptide angiotensin-(1-7) mimic, inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice. J Mol Med (Berl). 2020. 2020. Preclinical: animal or lab study. Population: Apolipoprotein E knockout mice. Aneurysms in 48% (low dose) and 28% (high dose) versus 76% with vehicle. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/32060588/)
3. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009. 2009. Human study (early or uncontrolled). Population: Adults with advanced solid tumours not responding to standard therapy (n=18). One patient had a 19% tumour reduction and three had stable disease beyond 3 months. Research on a related compound, not this one. Limitations: Studied an analog, not Angiotensin (1-7) Analog itself [Source](https://pubmed.ncbi.nlm.nih.gov/19920106/)
4. Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Sarcoma. 2016. 2016. Human study (early or uncontrolled). Population: Adults with metastatic sarcoma (n not stated in the indexed abstract). Well tolerated; median progression-free survival 2.7 months; the biomarker effect seen in phase 1 was not confirmed. Research on a related compound, not this one. Limitations: Studied an analog, not Angiotensin (1-7) Analog itself [Source](https://pubmed.ncbi.nlm.nih.gov/27895527/)
5. Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. Ann Intensive Care. 2024. 2024. Human study (early or uncontrolled). Population: Adults with COVID-19 pneumonia in intensive care (28 in phase 1, 79 in phase 2). No significant difference in oxygen-free days in phase 2; one bradycardia possibly related to infusion; stopped early for slow recruitment. Research on a related compound, not this one. Limitations: Studied an analog, not Angiotensin (1-7) Analog itself [Source](https://pubmed.ncbi.nlm.nih.gov/39231898/)

## Safety

Side effects: Limited human data; Hypotension possible in models.

Risks: Research-only; Not a substitute for ACE inhibitors/ARBs.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Angiotensin (1-7) Analog is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Angiotensin (1-7) Analog?

Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.

### How does Angiotensin (1-7) Analog work?

Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

### Is Angiotensin (1-7) Analog FDA approved?

No. Angiotensin (1-7) Analog is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Angiotensin (1-7) Analog?

Reported half-life for Angiotensin (1-7) Analog is Short; orally active analog tested in rodents. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to Angiotensin (1-7) Analog?

Compounds most often compared with Angiotensin (1-7) Analog include 5-Amino-1MQ, Adipotide, AICAR and AOD-9604. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress — Psychopharmacology (Berl), 2026](https://pubmed.ncbi.nlm.nih.gov/42440117/)
- [Angiotensin 1-7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion — Biomedicines, 2025](https://pubmed.ncbi.nlm.nih.gov/40149544/)
- [PNA5, a glycosylated angiotensin-(1-7) mas receptor agonist for vascular dementia: A two species toxicology and toxicokinetic study — Toxicol Rep, 2025](https://pubmed.ncbi.nlm.nih.gov/41246188/)
- [PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and Dementia — Aging Dis, 2024](https://pubmed.ncbi.nlm.nih.gov/37815905/)
- [AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis — Sci Rep, 2024](https://pubmed.ncbi.nlm.nih.gov/39487232/)
